On February 21, 2022 Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) reported to conduct a $18.1 million equity raising via an accelerated 1 for 3.15 non-renounceable entitlement offer of fully paid ordinary shares in Chimeric (New Shares) to raise approximately $18.1 million (before costs of the offer)(Entitlement Offer) (Press release, Chimeric Therapeutics, FEB 21, 2022, View Source [SID1234608344]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The offer price for the Entitlement Offer will be $0.17 per share (Offer Price). The Offer Price represents:
• a 11.8% discount to the theoretical ex-rights price (TERP);2
• a 18.3% discount to the 5-day volume weighted average price (VWAP), and
• a 15.0% discount to the last traded price of Chimeric shares.
Under the Entitlement Offer, eligible shareholders will be able to subscribe for 1 new ordinary share in Chimeric for every 3.15 existing shares (and 1 new option for every New Share issued with an 1 Before costs of the offer 2 The theoretical ex-rights price of $0.193 is calculated using Chimeric’s closing price on 18 February 2022 assuming proceeds from the Entitlement Offer of $18.1 million. TERP is the theoretical price at which shares should trade immediately after the ex-date for the Entitlement Offer assuming 100% take-up of the Entitlement Offer. TERP is a theoretical calculation only and the actual price at which shares trade immediately after the ex-date for the Entitlement Offer will depend on many factors and may not be equal to the TERP. CHIMERIC THERAPEUTICS LIMITED ACN 638 835 828 LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA exercise price of $0.255 per new option and exercisable on or before 31 March 20243) held at 7pm (AEDT) on Wednesday, 23 February 2022(Record Date) at the Offer Price (Entitlements).
The Entitlement Offer includes an institutional component (Institutional Entitlement Offer) and a retail component (Retail Entitlement Offer).
The Entitlement Offer has been managed by Bell Potter Securities Limited. Bell Potter will receive fees for its lead manager and other services, to be settled in cash.
The Board intends to use the proceeds of the Entitlement Offer to fund payments under the Company’s licence and sponsored research agreements as well as Phase I clinical trials. Funds will also be applied for ongoing working capital and the costs of the Entitlement Offer.
Institutional Entitlement Offer
Eligible institutional shareholders will be invited to participate in the institutional component of the Institutional Entitlement Offer, which is being conducted today, Monday, 21 February 2022. Eligible institutional shareholders can choose to take up all, part or none of their Entitlement. Institutional Entitlements cannot be traded on ASX or transferred. Institutional Entitlements that eligible institutional shareholders do not take up by the close of the Institutional Entitlement Offer, and institutional Entitlements that would otherwise have been offered to ineligible institutional shareholders, will be offered to new institutional investors and existing institutional shareholders concurrently with the Institutional Entitlement Offer. Chimeric’s shares will remain in a trading halt pending completion of the Institutional Entitlement Offer.
Retail Entitlement Offer Eligible retail shareholders in Australia and New Zealand will be invited to participate in the Retail Entitlement Offer at the same Offer Price and offer ratio as the Institutional Entitlement Offer. The Retail Entitlement Offer will open on 28 February 2022 and close at 5:00pm (Sydney time) on 11 March 2022. Further details about the Retail Entitlement Offer will be set out in the Retail Entitlement Offer prospectus (Prospectus), which Chimeric expects to lodge with ASX and dispatch to eligible retail shareholders on 28 February 2022. The Prospectus will also enclose personalised entitlement and acceptance forms.
The Entitlements are non-renounceable and will not be tradeable on ASX or otherwise transferable. Shareholders who do not take up their Entitlements will not receive any value for those 3 Institutional Shareholders must, at the issuance date of new Options, hold at least the number of New Shares they subscribed for under the Institutional Entitlement Offer. CHIMERIC THERAPEUTICS LIMITED ACN 638 835 828 LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA Entitlements that they do not take up. Shareholders who are not eligible to receive Entitlements will not receive any value for the Entitlements they would have received had they been eligible. Approximately 106.5 million new ordinary shares in Chimeric will be issued as part of the Entitlement Offer. Shares issued under the Entitlement Offer will rank equally with existing shares.
Approximately 106.5 million options over ordinary shares in Chimeric will be issued as part of the Entitlement Offer, with full details set out in the Annexure to the Prospectus. The Retail Entitlement Offer will include a top up facility under which eligible retail shareholders who take up their full Entitlement will be invited to apply for additional shares in the Retail Entitlement Offer from a pool of those not taken up by other eligible retail shareholders. There is no guarantee that applicants under this top up facility will receive all or any of the shares they apply for under the facility. Chimeric will notify shareholders as to whether they are eligible to participate in the Retail Entitlement Offer.
Eligible retail shareholders will receive an information booklet including a personalised entitlement and acceptance form which will provide further details of how to participate in the Retail Entitlement Offer. Also, under ASX Listing Rules, Appendix 7A, Chimeric will despatch a letter about the Entitlement Offer to each holder of options to subscribe for Chimeric shares. A presentation on the Entitlement Offer has been lodged with ASX today and is able to be downloaded from ASX’s website, www.asx.com.au.